MedTrace Logo

Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis

NCT01469507 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-02-21

No results posted yet for this study

Summary

The primary objective of this study is to compare a combination of hyaluronic acid and chondroitin sulfate (V0220) to Hyalgan® on pain relief in patients with symptomatic knee osteoarthritis (OA) over 24 weeks when administered in three weekly injections.

Chondroitin sulfate is one of the components of cartilage. Studies have shown that chondroitin sulphate improves the quality of the hyaluronic acid produced in the joint. The benefit of V0220 combination is based on two main physicochemical properties, in line with the characteristics of osteoarthritic disease: optimising the rheological behaviour and improving the buffering effect on synovial flow ("outflow buffering").

Conditions

Interventions

DEVICE

Chondroitin sulfate and sodium hyaluronate

3 weekly injections

DRUG

Hyaluronan

3 weekly injections

Sponsors & Collaborators

  • Pierre Fabre Medicament

    lead INDUSTRY

Principal Investigators

  • Emmanuel MAHEU, Dr · private practice / unaffiliated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01469507 on ClinicalTrials.gov